For instance, engineering CD19 CAR-T cells to constitutively express the pro-inflammatory cytokine IL-18 [90], has demonstrated improved CAR-T cell proliferation and anti-tumor activity compared to unarmored CD19 CAR-T cells and had adjuvant properties activating the endogenous immune system [88]. This evidence concerns the gene CD19 and neoplasm.